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Background: In the frame of a research line dedicated to better clarify the role of exopolysaccharides (EPS) in bacterial virulence, EPS
produced by species of the Burkholderia cepacia complex (Bcc), namely Burkholderia multivorans, Burkholderia cenocepacia, and a Bcc
member of undetermined genomovar, all isolated at the Cystic Fibrosis Regional Centre of Florence (Italy), were investigated for they
structural properties.
Methods: Three strains of B. multivorans, three of B. cenocepacia and one of a Bcc member of undetermined genomovar were isolated from
CF patients. The reference strains C1576 and J2315, for genomovar II and III, respectively, were included in the study. The bacteria were
grown on solid media, the exopolysaccharides produced were purified, and their structures were determined. In addition, sugar analysis of
sputum samples was accomplished to search for EPS produced in vivo.
Results: Six strains out of seven produced the exopolysaccharide cepacian, while one strain of B. multivorans produced a completely
different polymer, previously known in the literature as PS1. Two strains synthesised very small amounts of EPS. No definitive evidence for
the presence of cepacian in sputum samples was found.
Conclusions: Most strains examined produced abundant amounts of polysaccharides. Cepacian was the most common EPS isolated and its
production was not associated to a particular genomovar.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Burkholderia cepacia complex; Exopolysaccharide; Structure; Sputum samples1. Introduction
Bacterial exopolysaccharides (EPS) are important factors
contributing to infection maintenance. These biopolymers
are excreted in the medium surrounding bacteria where they
form a disperse coating around the cells. The macromole-
cular nature of the coating and its favourable interactions
with the aqueous environment increase the medium viscosity
immediately around bacterial cells. This property confers a⁎ Corresponding author. Tel.: +39 040 5583685; fax: +39 040 5583691.
E-mail address: cescutti@bbcm.units.it (P. Cescutti).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.06.004protecting role against phagocytosis, opsonisation and
dehydration [1,2]. In addition, a specific role against the
action of antimicrobial peptides of the innate immune system
has been proposed for bacterial EPS [3,4].
In cystic fibrosis (CF) patients, the composition of the
fluid covering the lung epithelium is altered, and the
mucociliary clearance is impaired, leading to colonisation
by different bacteria. Pulmonary infections due to opportu-
nistic pathogens are the major cause of death for CF patients
and many reports evoke the important role of bacterial EPS
in such infections. Studies carried out on Pseudomonas
aeruginosa, one of the most important pathogen for CFed by Elsevier B.V. All rights reserved.
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alginate [5]. More specifically, it was demonstrated that O-
acetylation of alginate modulates the resistance of mucoid
bacteria to antibody-independent opsonic killing [2]. In fact,
acetate residues are bound via ester linkages to EPS hydroxyl
groups that, when unsubstituted, may act as binding sites for
the C3b and C4b opsonins. The above results clearly
indicated a critical role for EPS in bacterial virulence and
also suggested a specific role of acetylation in the
modulation of bacterial resistance to the host immune
defences. Therefore, the detailed knowledge of the EPS
primary structure is a key factor in the investigation of
bacterial infections.
The Burkholderia cepacia complex (Bcc) is a group of
bacteria characterised by similar phenotype, but different
genotype. The complex comprises nine different genomo-
vars, each of which received a name species [6]. Although
strains of each genomovar can colonise the lungs of CF
patients, Burkholderia multivorans (genomovar II) and
Burkholderia cenocepacia (genomovar III) are responsible
for the majority of infections. The EPS produced by Bcc
strains were investigated in several different laboratories, but
usually these studies were not paralleled by the assignment of
microbial species, except in a recent publication, where EPS
from clinical and environmental strains of B. cenocepacia
were compared [7]. Most of the Bcc strains investigated in
different parts of the world produced only one type of EPS
[8–12], to which the name cepacian was assigned [13]. The
polysaccharide is constituted of a branched heptasaccharide
repeating unit (Fig. 1), and is characterised by high molecular
weight, a certain degree of chain rigidity and capacity of
aggregates formation [13,14]. Only a small percentage ofFig. 1. Chemical structures of thBcc strains examined produced EPS completely different
from cepacian [15,16] and their structures are reported in Fig.
1. The critical role of the Bcc EPS in CF infections was
recently demonstrated in a mouse model, where a sponta-
neous variant of a Bcc strain persisted in the lungs longer
than the parent strain and was characterised by abundant EPS
production [12]. In addition, it was proved that the EPS of a
B. cenocepacia isolate inhibited neutrophils chemotaxis and
scavenged reactive oxygen species, which in vivo are
produced by neutrophils to kill bacteria [17].
In the present paper, we further pursued the investigation
of EPS from Bcc, taking into consideration clinical strains of
B. multivorans and B. cenocepacia isolated from CF patients
attending the Cystic Fibrosis Regional Centre of Florence. A
strain of a Bcc member with unknown genomovar [18]
isolated from a CF patient was included in the research work.
This is the first investigation on the EPS produced by B.
multivorans clinical isolates. Furthermore, with the aim of
determining the presence of EPS in vivo, sputum samples
were analysed for the presence of EPS.
2. Materials and methods
2.1. Bacterial strains
Nine bacterial strains presumed to belong to the Bcc were
isolated from 7 out of 167 (4%) patients attending the Cystic
Fibrosis Regional Centre of Florence. All bacterial strains
were isolated following international guidelines, and tenta-
tively identified as B. cepacia complex using commercial
tests. The isolates were stored at −80 °C. Bcc genomovar
status was determined by the European Burkholderiae EPS produced by Bcc.
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(Laboratorium voor Microbiologie, Universiteit, Gent)
using a polyphasic approach, including whole cell protein
electrophoresis, and recA restriction fragment length poly-
morphism (RFLP) analysis by means of the restriction
enzymes HaeIII and MnlI [19,20]. Three isolates were B.
multivorans, three were B. cenocepacia, while the genomo-
var status of one isolate remained undetermined. The latter
isolate belongs to the Bcc, but its taxonomic status has not
yet been clarified (Table 1) [18]. The reference strains C1576
(B. multivorans) and J2315 (B. cenocepacia) were also
included in this study.
2.2. RAPD typing of Bcc isolates
DNA from each isolated colony was prepared by
heating one colony at 95 °C for 15 min in 20 μl of lysis
buffer containing 0.25% (wt./vol.) sodium dodecyl sulfate
(SDS) and 0.05 M NaOH. Following lysis, 180 μl of
distilled water was added and DNA solutions were stored
at 4 °C. RAPD fingerprinting was performed with primer
RAPD-270 (5′–TGCGCGCGGG–3′) as described pre-
viously [21] (PCR products were separated on 2% agarose
gels in 0.5 TBE buffer (80 mA for 4 h at room temperature).
Gels were stained with etidium bromide and visualized by
UV illumination.
2.3. Patients
The 7 Bcc colonized patients were in a stable clinical
condition except for one patient, colonised by B. multi-
vorans, who died without showing symptoms of B. cepacia
syndrome. Bcc colonization did not affect pulmonary
function being the average annual decline of FEV1 of
−1.9%, in agreement with the mean yearly decline reported
for CF patients (−1.29% to −3%) [22].
2.4. Isolation and purification of the exopolysaccharides
Bacterial cells were grown for 4 or 5 days at 30 °C on a
solid medium containing 2 g of yeast extract, 20 g ofTable 1
Bacterial strains, related genomovar and EPS produced
Strain Species Genomovar EPS/Petri
dish (mg)
BFI4 nd nd 42
BFI6 B. multivorans II 5
BFI8 B. cenocepacia III 48
BFI9 B. multivorans II 46
BFI11 B. multivorans II 32
BFI12 B. cenocepacia III 27
BFI13 B. cenocepacia III nm
C1576 B. multivorans II 8
J2315 B. cenocepacia III nm
nd=not determined.
nm=non-mucoid.mannitol and 15 g of bacto agar/l [23] (medium YEM). The
isolation and purification of the EPS was performed as
already described [7].
2.5. General analytical methods
Analytical GLC was performed with an AutoSystem XL
(Perkin Elmer) gas chromatograph equipped with a flame
ionisation detector, using He as the carrier gas. GLC–MS
analyses were carried out on a Hewlett-Packard 5890 gas
chromatograph coupled to a Hewlett Packard 5971 mass
selective detector.
Hydrolysis of the EPS was carried out in 2 M CF3CO2H
at 125 °C for 1 h. The O-acetyl groups were removed by
treatment with 0.01 M NaOH at room temperature for 5 h
[24].
2.6. Composition analysis of exopolysaccharides
Alditol acetates were prepared as described previously
[25] using inositol as internal standard. The derivatives were
separated by GLC using a SP2330 capillary column
(Supelco, 30 m) and the temperature program: 1 min at
200 °C, 200–245 °C at 4 °C/min, 20 min at 245 °C.
2.7. Linkage analysis
The samples were sonicated to reduce the molecular
weight and exchanged into the protonated form prior to
chemical reactions. Methylations were performed according
to Dell [26] but using potassium methylsulfinyl–methanide
[27]. After methylation, the permethylated samples were
purified on Sep-Pak C18 cartridge [28], prior to hydrolysis,
and derivatisation into alditol acetates. The products were
analysed by GLC and GLC–MS using an SP2330 capillary
column (Supelco, 30 m), and the temperature program: 1 min
at 150 °C, 150–250 °C at 4 °C/min, 20 min at 250 °C. Molar
ratio values were corrected by use of effective carbon-
response factors [29].
2.8. 1H NMR spectroscopy
NMR spectra were recorded on a Varian UNITY
INOVA NMR spectrometer operating at 500 MHz (1H)
at 50 °C. Samples, previously sonicated to decrease the
molecular weight, were exchanged three times with 99.9%
deuterium oxide by lyophilisation, and finally dissolved in
99.96% deuterium oxide. Chemical shifts are expressed in
ppm using as reference the HOD signal at 4.57 ppm at
50 °C.
2.9. Sugar analysis of CF sputum
Eight sputum samples from CF patients infected by Bcc
strains were available for sugar analysis in two years span.
Three sputum samples from patients infected only by P.
Table 2
Molar ratio of neutral sugars relative to glucose in the polysaccharides
samples compared with data for cepacian
Sugar Cep a BFI4 BFI6 BFI8 BFI9 BFI11 BFI12 C1576
Rha 0.81 0.80 0.04 0.85 0.81 0.73 0.79 2.22
Man 0.55 0.44 0.03 0.41 0.34 0.43 0.52 1.64
Gal 2.14 2.28 0.98 2.27 2.18 2.01 2.14 2.60
Glc 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
a Cep=data obtained on cepacian in a previous investigation [9].
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were tested; here the one that gave the best results is reported
and it was successfully applied to the available samples. The
samples were suspended in the minimum amount of water in
order to have a volume suitable for ultracentrifugation
(105,000×g, at 4 °C for 4 h). The supernatants were then
heated at 80 °C for 15 min, followed by centrifugation at
17,000×g, at room temperature for 10 min. To the super-
natants an equal volume of a 1% solution of N-acetyl-L-
cystein was added, the solutions were thoroughly mixed and
let them stand for 10 min. After dialysis against water, they
were treated with DNAse, RNAse and protease in 0.05 M
Tris–HCl, pH 7.5, 0.01 M MgCl2. After a further dialysis,
the samples were hydrolysed, derivatised and analysed as
described in Sections 2.5 and 2.6.
3. Results
3.1. Exopolysaccharides production
The bacteria were grown on solid medium containing
an excess of mannitol as carbon source [23] (medium
YEM), which efficiently discriminated mucoid from non-
mucoid strains. Strains BFI4, BFI6, BFI8, BFI9, BFI11,
BFI12 and C1576 were mucoid and most produced
abundant quantity of EPS (Table 1). In particular, two
isolates of BFI8 had a different phenotype: the one isolated
in 2001 was non-mucoid, while the one isolated in 2004
showed a highly mucoid character, and was used in this
study. However, these two isolates showed a unique RAPD
fingerprint revealing that the patient was persistently
colonized by the same clone. Isolate BFI13 and theTable 3
Linkage analysis of polysaccharides
Linked Relative molar ratios
Sugar a RRTb Cep c BFI4 BFI6
2-Rha 0.81 0.98 1.13
t-Gal 0.88 2.82 2.94
3-Glc 1.00 1.00 1.00 1.00
6-Gal 1.14
3,6-Man 1.26 0.42 0.73
3,4,6-Gal 1.37 0.92
a The numbers indicate the position of the glycosidic linkage, t stands for non-r
b Retention time relative to 3-linked glucose.
c Cep=data obtained on cepacian in a previous investigation [9].reference strain J2315 were non mucoid, therefore they
were not investigated further.
3.2. Composition analysis of exopolysaccharides
The composition of the exopolysaccharides was obtained
after hydrolysis of the polymers and derivatisation into
alditol acetates. As reported in Table 2, where data for
cepacian [9] are also shown, most of the EPS contained
rhamnose, mannose, galactose and glucose in amounts
similar to cepacian. The reference strain C1576 was com-
posed of the same sugars, but the molar ratios were quite
different from those of cepacian. Strain BFI6 was composed
of equimolar amounts of galactose and glucose, thus indi-
cating a polymer completely different from cepacian.
3.3. Linkage analysis
The EPS were subjected to linkage analysis and the
results are reported in Table 3, in comparison with the data
for cepacian [9]. Sample BFI6 was composed of equimolar
amounts of 3-linked glucose and 3,4,6-linked galactose, thus
revealing a polysaccharide with two sugar residues per
repeating unit. Moreover, the multiply substituted galactose
residue not accompanied by nonreducing terminal sugars
indicated the presence of a non-carbohydrate substituent.
The polysaccharides BFI4, BFI8, BFI11 and C1576
contained 2-linked rhamnose, non-reducing terminal-galac-
tose, 3-linked glucose and 3,6-linked mannose, the same
residues found in cepacian. On the contrary, samples BFI9
and BFI12 contained, apart from the residues mentioned
above, also 6-linked galactose, thus indicating the co-
production of a polysaccharide different from cepacian.
Sugar residues present in less than 10% were not considered.
3.4. 1H NMR and 13C NMR spectroscopy
All EPS, both in the native and de-acetylated form, were
studied by means of NMR spectroscopy. The 1H NMR
spectra recorded on the native samples showed signals
compatible with the polysaccharide cepacian, except for
BFI6, whose spectrum (Fig. 2a) was deeply different fromBFI8 BFI9 BFI11 BFI12 C1576
1.30 0.86 1.01 0.88 1.23
2.75 2.40 2.84 2.16 2.27
1.00 1.00 1.00 1.00 1.00
0.35 0.25
0.57 0.64 0.70 0.51 0.50
educing terminal.
Fig. 3. Partial anomeric regions of the 1H NMR spectra of the de-acetylated
exopolysaccharides BFI11, BFI4, and BFI8.
Fig. 2. 1H and 13C NMR spectra of the sample BFI6 recorded at 50 °C (a and
b), and 1H NMR spectrum of the polysaccharide cepacian recorded at 80 °C
(c). The principal regions of the spectrum are shown.
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the BFI6 1H NMR spectrum two signals at 5.42 and
4.72 ppm, with identical integration values, were present,
indicating a polysaccharide constituted of a disaccharidic
repeating unit. In the high field region of the spectrum the
signal at 1.47 ppm was assigned to the –CH3 protons of
pyruvyl groups; its integration value, equal to 3.4 with
respect to each of the anomeric signals, showed that there
was one pyruvyl group per repeating unit. 1H and 13C NMR(Fig. 2b) spectra, together with compositional and linkage
analysis, showed that the primary structure of the EPS BFI6
is identical to that one of the polysaccharide PS1 produced
by a Bcc clinical strain and described by Cérantola et al.
[15].
The 1H NMR spectra of all the other polysaccharides
showed signals attributable to –CH3 of rhamnose residues
(∼δ 1.3) and –CH3 of O-acetyl groups (δ 2.2–2.0).
Integration values of the methyl signals of the acetyl groups
were calculated with respect to the methyl signal for the
rhamnose residue. The data showed a content of acetyl
substituents in the range 2.3–3.4, indicating the presence of
Table 4
Molar percentages of neutral sugars in the sputum samples of 1 patient
colonised only by strain BFI4 (S4-1 and S4-2), 2 patients colonized by P.
aeruginosa and strain BFI8 (S8-1 and S8-2) or BFI11 (S11-1), and 3
patients colonized by P. aeruginosa (PA1-3)
Sugar Sputum samples
S4-1 S4-2 S8-1 S8-2 S11-1 PA-1 PA-2 PA-3
Rha 3.74 6.06 4.20 3.81 1.98 2.30 1.28 2.30
Fuc 14.18 4.48 8.83 11.68 18.60 16.15 21.27 13.44
Ara 17.46 27.36 20.99 17.85 7.18 14.74 4.29 15.59
Xyl 1.66 – – – – – 1.15 –
Man 15.38 15.23 16.68 21.26 17.92 15.54 14.18 19.09
Gal 42.96 39.64 38.54 32.28 47.47 46.99 53.69 44.43
Glc 4.62 7.22 10.76 13.12 6.80 3.67 4.12 5.10
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unit. Only the sample C1576 had a content of acetyl groups
equal to 1 substituent per repeating unit. The 1H NMR
spectra of the de-acetylated polysaccharides BFI4, BFI8,
BFI9, BFI11, BFI12, and C1576 were recorded and their
anomeric regions are reported in Figs. 3 and 4. The EPS
BFI11 (Fig. 3) showed only signals identical to those of
cepacian, except for two small shoulders, at 5.51 and
5.20 ppm, and a very small signal at 5.46 ppm, indicating
that the polysaccharide consists of almost pure cepacian.
Samples BFI4 and BFI8 (Fig. 3), showed the signals
typical of cepacian, but some of them differed for their
intensity. Moreover, further anomeric signals at 5.53, 5.44
and 5.00 ppm established that the two samples were a
mixture of polymers, one of which was identical to
cepacian. The polymers BFI9 and BFI12 (Fig. 4) had the
same characteristic of BFI4 and BFI8, but they were even
more stressed, thus suggesting a relatively higher amount
of polysaccharides different from cepacian. Finally, the
EPS C1576 had the most complicated anomeric regionFig. 4. Partial anomeric regions of the 1H NMR spectra of the de-acetylated
exopolysaccharides BFI9, BFI12, and C1576.among the samples examined, with signals belonging to
cepacian and other proton signals attributable to different
exopolysaccharides.
3.5. Sugar analysis of CF sputum
Eight samples of sputum from CF patients were subjected
to purification in order to determine the presence of EPS.
Two samples were from patients infected only with BFI4
(S4-1 and S4-2), two were co-infected with BFI8 and P.
aeruginosa (S8-1 and S8-2), and one with BFI11 and P.
aeruginosa (S11-1). It is worth stressing that these strains
produced mainly the EPS cepacian in vitro. The other three
samples gave poor results and therefore were not reported.
Hydrolysis of the purified sputum and derivatisation of the
neutral sugars to alditol acetates was followed by GLC
analysis. The results are reported in Table 4. The sugars
detected in the hydrolysates were rhamnose, fucose,
arabinose, mannose, galactose, and glucose; in one sample
xylose was also present. The same purification procedure
and analysis were applied to three samples from patients
colonised only with P. aeruginosa, used as control. The
results indicated the presence of the same sugars, although in
different amounts (Table 4).
4. Discussion
This study deals with the isolation and identification of
EPS produced by clinical isolates of B. multivorans and B.
cenocepacia; EPS from the former species has never been
investigated before. The reference strains C1576 (B. multi-
vorans) and J2315 (B. cenocepacia) and a Bcc strain of
unknown genomovar were included in this research work.
For the first time, sputum samples of CF patients infected
with some of the strains reported above were analysed for the
presence of EPS.
The EPS structure was determined by use of chemical
analysis coupled to gas chromatography and mass spectro-
metry, and by 1H and 13C NMR spectroscopy analysis. The
data showed that strain BFI6 produced a polysaccharide
identical to PS1 [15] and this is the first time that the
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investigated by Cérantola et al., is reported. All the other
strains produced the EPS cepacian, almost pure in one case
(BFI11) or together with small amounts of other poly-
saccharides whose primary structure was not identified. Only
the strain C1576 produced a mixture of EPS where the
unknown component was rather abundant. As previously
reported for other strains belonging to the Bcc [7], no
connection between type of EPS produced and Bcc species
was observed, cepacian remaining as the most common EPS
produced.
Sputum samples from CF patients infected by Bcc
strains were analysed for the presence of EPS, via
hydrolysis of the polysaccharides and GLC analysis of
the derivatives. Besides the experimental protocol reported
in Section 2.9, other attempts to purify the EPS from the
biological samples were made. In particular, affinity and
cation exchange chromatography were experimented to
eliminate the mucin component, but both proved unsuc-
cessful. Detection of uronic acids, not present in glyco-
proteins, as performed with CF sputum from patients
infected by P. aeruginosa [30], was not suitable for two
reasons. One is that a colorimetric method is rather
unspecific in this case, because Bcc microorganisms
produced different EPS, some of them containing no
uronic acids. The second reason is the detection limit of the
colorimetric method. In fact, not only the uronic acid
concentration in cepacian is rather low (∼16% w/w), but
the concentration of EPS in sputum is also rather low, as
determined for alginate (average concentration =37 μg/ml)
[30]. The sugars that constitute the EPS cepacian, were all
present in the sputum samples, even if in different amounts.
However, other sugars like fucose, arabinose and xylose,
never found to be part of EPS produced by Bcc, were
present. The data can be explained by the presence of
mucins and contamination with blood. Bronchial mucins
are highly glycosylated and their sugar composition
consists mainly of fucose, galactose, N-acetyl glucosamine,
N-acetyl galactosamine and sialic acid [31–35]. Therefore,
the high content of fucose and galactose could derive from
the carbohydrate moiety of mucins. At the same time it was
reported that the seromucoid fraction of human serum
contained fucose, arabinose, mannose, glucose, galactose,
glucosamine and galactosamine [36]. Rhamnose was not
reported to be a component of the macromolecules
mentioned above and therefore it is reasonable to correlate
its presence with that of cepacian. In particular, in the
samples S4-1 and S4-2, which were contaminated
exclusively by Bcc, the average value of rhamnose content
was 4.90. The molar percentages of rhamnose are higher in
these samples than in PA-1, PA-2, and PA-3 (average
value 1.96), where most likely it derived from hydrolysis
of the rhamonolipid component, since these samples were
contaminated only by P. aeruginosa. Samples S8-1, S8-2
and S11-1, which were contaminated by Bcc and P.
aeruginosa, also contained rhamnose, as expected, andinterestingly the average value (3.33) was in between those
of the previous samples (Table 4). In conclusion, the data
obtained do not allow an unambiguous proof of the
presence of cepacian in vivo due to the interference of
other carbohydrates in sputum, like rhamnolipids and those
contained in mucin. Nevertheless, the amount of rhamnose
in sputum samples contaminated only by Bcc was higher
than that found in samples contaminated only by P.
aeruginosa suggesting the presence of Cepacian in vivo.
However, the number of biological samples examined was
not high enough to obtain a good statistics, a problem
related to their availability from CF medical centres and to
the patients' clinical conditions.
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